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Introduction. Bone-marrow-derived mesenchymal stem cells (MSCs) have been studied for treatment of myocardial infarction
(MI). Since MSCs from older donors show quantitative and qualitative senescent changes, we hypothesized that a better outcome
may be achieved if aged recipients are given MSCs obtained from young donors, rather than using their own autologous MSCs.
Methods. In vitro studies compared properties of young and old MSCs. Aged rats randomized into 3 groups underwent coronary
artery ligations and were then injected with either old (O) or young (Y) MSCs, or ligation alone. Echocardiography evaluated ejec-
tion fractions (EF). At 16 weeks, scar deposition was analyzed. Results. Old MSCs exhibited decreased cell viability, proliferation,
and diﬀerentiation potentials. EF signiﬁcantly improved early in both cell therapy groups (P<. 05). However, at later stages of the
study, group Y showed signiﬁcantly better function which correlated with decreased scar deposition. Conclusions. The signiﬁcant
diﬀerence between young and old cells indicates the possible advantage for allotransplanting MSCs from young donors to elderly
patients with MI.
1.Introduction
Coronary artery disease remains a major cause of morbidity
and mortality in developed nations. Recently, several animal
models and clinical trials have demonstrated the therapeutic
eﬀect of mesenchymal stem cells (MSCs) to improve cardiac
function following an acute myocardial infarction (MI) [1,
2] .T h e s ec e l l sa r ea b l et od i ﬀerentiate into a variety of cell
phenotypes [3], including cardiomyocytes, and can upregu-
late anti-inﬂammatory cytokines in the host microenviron-
ment [4]. Furthermore, our lab and others have demon-
strated that MSCs are immune tolerant such that they can be
used in allogenic and even xenogenic transplants [1, 2, 5–7].
Since patients most likely to beneﬁt from cell therapy for
the treatment of acute MI are the elderly, it is important to
consider the eﬀects of aging on donor MSCs. In vitro studies
involving MSCs have shown that an increased donor age is
associated with decreased proliferation rates [8, 9]. Further-
more, studies that compared aged and young MSCs have
shown an age-related decrease in diﬀerentiation potential
[10–12]. These changes in the cellular characteristics are due
to intrinsic changes within the cell as well as the eﬀects
of the aged microenvironment. Considering the eﬀects of
aging on MSCs and the target population of cell therapy,
a better strategy for treatment of an acute MI could therefore
involve isolating these cells from young donors for allotrans-
planation into the elderly, rather than using their own aging
autologous cells.
Based on this background, our objective was to compare
the in vitro properties and in vivo therapeutic eﬀect of young2 Journal of Tissue Engineering
versus old MSCs in an aging rodent model of acute MI. We
hypothesized that old MSCs will have a decrease in their po-
tential to improve cardiac function following an acute MI
when compared with MSCs harvested from younger donors.
2.MaterialsandMethods
2.1. Animals. Immunocompetent female syngenic Sprague
Dawley (SD) rats (400–450g, Charles River, QC, Canada)
were used. All procedures were in compliance with the Guide
for the Care and Use of Laboratory Animals (NIH publica-
tion number 85—23) and the Guide to the Care and Use of
Experimental Animals of the Canadian Council on Animal
Care.
2.2. Isolation, Labelling and Culture of Rat MSCs. MSCs
harvested from young (6-weeks-old) and old rats (54-weeks-
old) were cultured and prepared according to Caplan’s
method. Brieﬂy, bone marrow aspirates were passed through
a density gradient, and hematopoietic cells, ﬁbroblasts, and
other nonadherent cells were washed away during medium
changes. As has been done in previous studies, the remaining
puriﬁed MSC population was further expanded in culture
using 10% fetal bovine serum supplemented DMEM media
to form a clonal homogenous population of cells [6, 7]. The
resulting MSCs were expanded for transplantation.
2.3. In Vitro Cell Proliferation Assay. The cell prolifer-
ation was evaluated using the Cell Titer 96 Aqueous
Non radioactive Cell Proliferation MTS Assay (Promega,
Madison,WI).MTSischemicallyreducedbyviablecellsinto
formazan, which is soluble in tissue culture medium. The
dehydrogenase enzyme activity found in the metabolically
active cells is measured in terms of light absorbance values
in this assay. The measurement of the absorbance of the
formazan was carried out using the plate reader (Victor3
Multilabel Counter from Perkin Elmer) at 490nm. Since the
production of formazan is directly related to the number
of living cells, the intensity of the produced color is an
indicator of the viable cells. For this, the cells were seeded
in a 96-well plate with 2 × 104 cells per well using serum-
supplementedDMEM.After4days,theproliferationtestwas
done by MTS assay as per the manufacturer’s instructions
mentioned elsewhere [13]. The experiments were performed
in triplicates.
2.4. In Vitro Hypoxic Induction Assay. For the hypoxia exper-
iment, the cells were seeded in 96-well plates as mentioned
earlier with 2 × 104 cells per well and incubated overnight.
The cells were then washed twice with PBS and replaced
with serum-free DMEM media. The hypoxic condition was
then generated using a hypoxia modular incubator chamber
(Billups-Rothenburg Inc., Del Mar, CA) according to the
protocol mentioned elsewhere [14]. Brieﬂy, the cell culture
plates were enclosed in the chamber and ﬂushed with
a mixture of gases (95% N2 and 5% CO2)f o r5m i n u t e s .
At the end of the ﬂushing period, the chamber was closed
to prevent free ﬂow of exogenous air into the chamber.
T h eﬁ n a ll e v e lo fh y p o x i aw a sa r o u n d1 % .T h ec e l l sw e r e
maintained under this hypoxic serum-free condition for 16
hours inside the 37◦C incubator before they were taken out
for proliferation studies.
2.5. Adipogenic and Osteogenic Diﬀerentiation of MSCs. To
induce diﬀerentiation, young and old MSCs were ﬁrst seeded
in 24-well plates at a high conﬂuency using serum supple-
mented DMEM media. After 24 hours of culture, the media
were replaced with either osteogenesis induction media or
adipogenesis induction media (Millipore, Billerica, MA) to
induce diﬀerentiation [15, 16]. During this period, the in-
duction media were replaced every alternate day with fresh
induction media and later, diﬀerentiation media according
to the manufacturer’s protocol. After an induction period of
3 weeks, the cells were stained with either Oil Red O stain,
which stains the lipid molecules, to assess adipogenic dif-
ferentiation or Alizarin Red stain, which stains mineralized
extracellular matrix, to assess osteogenic diﬀerentiation.
2.6. In Vivo Experimental Design. Immunocompetent SD
rats, approximately 56-weeks-old, underwent proximal left
anterior descending coronary artery ligations and were ran-
domly assigned into three groups (group L, n = 5; group
Y, n = 8; group O, n = 7). In group L, coronary arteries
were ligated without cell injections as control. In group Y,
young rat MSCs (3 × 106 cells) suspended in 150µLo f
culture medium were injected transmurally around the peri-
infarct area of the rat left ventricle (LV), 10 minutes after
coronary ligation. In group O, rat MSCs (3 × 106 cells) from
old donors were similarly injected as above after coronary
ligation. All rats survived for the duration of the study which
was predetermined to be 16 weeks.
2.7. Functional Assessment Using Echocardiography. Trans-
thoracic echocardiography was performed on all rats at base-
line and biweekly for 16 weeks after ligation and stem cell
therapy. All animals were sedated in a quiet room and
positioned in a right lateral decubitus fashion to ensure
similar views in all echocardiographic assessments. An ech-
ocardiographic system was obtained commercially using
a 12MHz probe with small footprint (SonoSite, Seattle, WA)
and performed as previously described [7]. The heart was
scanned in longitudinal view in 2D and M-mode where it is
usually possible to see a two-chamber view. Then, the probe
was turned 90 degrees to get the best possible cross-sectional
view of the left ventricle just above the papillary muscles.
To minimize the intraobservational error in measurements,
three consecutive measurements were made and averaged.
Left ventricular end-diastolic (LVEDD) and end-systolic
(LVESD) diameters were measured. This was done according
to the American Society of Echocardiology leading-edge
method [17]. Fractional shortening was determined as
[(LVEDD-LVESD)/LVEDD] × 100 (%). The ejection frac-
tion (EF) was estimated as [(LVEDV-LVESV)/LVEDV] ×
100 (%). All pre- and post-intervention measurements were
performed by one experienced observer blinded to the treat-
ment groups to ensure reproducibility.Journal of Tissue Engineering 3
2.8. Heart Specimen Harvesting and Histopathological Analy-
sis. Upon sacriﬁce at 16 weeks, hearts from all groups were
harvested and dissected from surrounding tissue. Five con-
secutive 5µm sections were prepared from the mid-portion
of the infracted area in all samples. Sections were stained
with collagen-speciﬁc dye Sirius red 3BA in saturated picric
acid solution to allow a clear discrimination between car-
diomyocytes and extracellular collagen matrix (ECM). The
slides were scanned at 2400dpi with 4x magniﬁcation, and
the pictures were RGB split to green color layer for mea-
surement. In the digital images, scar area and the total area
of myocardium were traced manually by a blinded observer
and measured automatically by the computer by means of
Image J-1.41 software. Infarct size, expressed as a percentage,
was calculated by dividing the sum of infarct areas by the
totalsumofLVareasincludingthosewithoutinfarctscarand
multiplying by 100.
2.9.StatisticalAnalysis. A lldataar ee xp r essedasmeanval ues
± standard deviation. Analysis was carried out by using SPSS
16.0 software (SPSS Inc, Chicago, IL). Comparisons between
the three groups were made using one-way analysis of var-
iance (ANOVA) with a Tukey’s post hoc. Comparisons bet-
ween two groups were done using Student’s t-test. Statistical
signiﬁcance was deﬁned as P-value less than .05 for all tests.
3. Results
3.1. In Vitro Assessment
3.1.1. Stem Cell Proliferation Capability. Cell proliferation
assays were performed on passages 1, 5 and 10 of both cell
types. Cells were seeded with 2 × 104 cells per well and
after 4 days MTS cell proliferation assay was done. Both
cell types had rapid and highest proliferation in passage
5, while with higher passages, such as at passage 10, the
proliferation potential decreased (Figure 1(a)). Young MSCs
hadsigniﬁcantlyhigher(P<. 05)proliferationpotentialthan
old MSCs at every passage.
3.1.2. Stem Cell Response to Hypoxic Condition. Sixteen hour
hypoxia under serum free conditions had no major eﬀect on
cellviabilityofyoungMSCsinpassages1and5(Figure1(b)).
However, this was not the case with old MSCs, where there
was a marked reduction in cell viability (Passage 5: Group
Y 97.0% ± 1.2% versus Group O 78.0% ± 2.1%, P<. 05).
Young MSCs maintained a signiﬁcantly higher viability in
passage10underserumfreehypoxicconditionsascompared
tothatofoldMSCs.ThisdatashowedthatyoungMSCswere
much more suitable for cell therapy after an acute MI than
their older counterpart.
3.1.3. Stem Cell Diﬀerentiation to Osteogenic and Adipogenic
Lineages. The osteogenic diﬀerentiation of old and young
MSCs were examined using the osteogenesis and adipogene-
sis induction media. Both cell types were able to diﬀerentiate
to the induced lineages, although qualitatively it was demon-
strated that young MSCs tended to diﬀerentiate readily and
betterthantheolderones(Figure2).Theseresultsconﬁrmed
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Figure 1: (a) The normalized data (young MSCs at passage 1 has
been taken as 1.0, and other values are normalized to it) demon-
strates highest proliferation in passage 5, compared to passages 1
and 10, with group Y having signiﬁcantly higher proliferation rates
than group O at all passages (∗P<. 0 5 ) .( b )T h ed a t ad e m o n s t r a t e s
that there is no major eﬀect of hypoxic condition on young MSCs
in all the passages compared to old cells (∗P<. 05).
the multipotency of the cells studied, an important property
of stem cells.
3.2. In Vivo Assessment
3.2.1. Functional Improvement of MSC-Treated Hearts. The
left ventricular ejection fraction (LVEF) was not signiﬁcantly
diﬀerentamongthegroupspreoperatively.Overall,therewas
a signiﬁcant improvement in LVEF in the two cell therapy
groups compared to the control group L, indicating a ben-
eﬁcial eﬀect of MSC therapy after MI (Figure 3). However,
at a later stage beyond 10 weeks of follow-up, group Y
demonstrated much more signiﬁcant improvement in LVEF,
while the old MSC group assumed a similar decline pattern
as control group L.
Preoperative fractional shortening was also similar
among the 3 groups prior to cell therapy. A rather similar
pattern was also observed between the cell therapy groups
versus control group, although the separation of the young
donor group occurred at a slightly later time (Figure 4).
3.2.2. Left Ventricular Scar Area Analysis. Histopathological
analysis of myocardial tissues showed signiﬁcantly reduced
scar extracellular matrix deposition in group Y at 16 weeks
compared to group O and group L (Figure 5).4 Journal of Tissue Engineering
Group Y Group O
(a) Adipogenic diﬀerntiation
Group Y Group O
(b) Osteogenic diﬀerntiation
Figure 2:Thecells,frompassage5,wereseededathighconﬂuencyforosteogenicandadipogenicdiﬀerentiationusingserum-supplemented
DMEM.Afterovernightculture,themediawasreplacedwithrespectiveinductionmedia.After21daysofosteogenicinduction,thecellswere
stained with alizarin red to detect the osteogenically diﬀerentiated cells. Similarly the cells were stained with oil red O to detect the mature
adipocytes. Both cell types showed diﬀerential potential, with young cells being more eﬃcient.
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Figure 3: Echocardiography demonstrated that left ventricular
ejectionfractionsimprovedinbothcelltherapygroupscomparedto
thecontrolgroup.Furthermore,therewasanoverallobservedtrend
that the group that received cells from young donors experienced
the greatest improvement in ejection fraction following acute MI
(∗Group O versus Group Y, P<. 05; †Group O versus Group L,
P<. 05; ‡Group Y versus Group L, P<. 05).
4. Discussion
Many studies have demonstrated that MSCs isolated from
older donors undergo senescence and display several quali-
tative and quantitative changes compared to young donors
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Figure 4: There was an observed trend that left ventricular frac-
tional shortening improved in both cell therapy groups compared
to the control and when group O was compared to group Y, group
Y had an overall greater improvement in fractional shortening
(∗Group O versus Group Y, P<. 05; †Group O versus Group L,
P<. 05; ‡Group Y versus Group L, P<. 05).
[8–12]. These observed age-associated changes may aﬀect
the therapeutic impact of cell therapy in an acute MI
setting. Since the clinical application of cell therapy is oftenJournal of Tissue Engineering 5
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Figure 5: (a) At 16 weeks, group Y experienced signiﬁcantly (∗P<. 01) decreased scar formation. (b) Sirius red staining shows collagen
deposition (scar) in red against cardiomyocytes and intramyocardial vessels in orange (original magniﬁcation x4).
relevant to the elderly patients, senescent stem cell donors
may provide less eﬃcient functional improvement following
cellular cardiomyoplasty. Our lab and others have shown
that MSCs are immune tolerant [1, 2, 7] and using MSCs
isolated from young donors for allogenic transplantation to
olderpatientswouldprovideabetteralternative.Thecurrent
in vitro data suggested that MSCs from young donors had
increaseddiﬀerentiationpotentialcomparedtoolderdonors.
In addition, the proliferation rates were also higher in the
young donors; therefore, expanding MSCs to large thera-
peutic doses after initial harvesting is much more feasible
when isolated from younger donors [18]. The present study
also provided an additional in vivo rodent model comparing
the therapeutic eﬀect of MSCs isolated from young versus
old donors to treat acute MI in aged recipient animals
and demonstrated that cells isolated from young donors
resulted in greater improvement of cardiac function and
decreased scar formation when compared to MSCs from
older donors. Both cell-treated groups also experienced an
increased ejection fraction compared to the control group,
demonstrating a therapeutic eﬀect of MSC implantation.
However, this beneﬁcial eﬀect gradually faded oﬀ over
longer-term follow-up in the aging MSC donor group. The
histopathological analysis showed that this functional deteri-
oration in rats treated with MSCs from aged donors (group
O) was associated with greater ECM deposition at 16 weeks
compared to the recipient rats with young donor MSCs. This
suggests that the local eﬀect of MSCs from older donors is
not long lasting compared with the younger counterparts.
The mechanism as of why the beneﬁcial eﬀects of MSCs at
diﬀerent ages only separated many weeks after implantation
is not well understood. A recent study by Chen et al. from
our lab has shown that the early functional improvement
of LV function after acute myocardial injury and stem
cell therapy was attributed to the anti-inﬂammatory eﬀect
of cytokine that was signiﬁcantly upregulated immediately
after MSC implantation, a mechanism that may explain the
early functional improvement before cell diﬀerentiation has
time to take place [6]. It is possible that the decline in
paracrineanddiﬀerentiationpotentialofagingMSCsmaybe
temporallydiﬀerentandmayexplainthetime-relateddecline
inMSCbeneﬁt.Forthisreason,anendpointof16weekswas
chosen prior to the start of the experiment to compare both
short-term and long-term eﬀects of transplanting young and
old stem cells.
The functional and histopathological results of age-re-
lated decline in therapeutic eﬀect of MSCs are consistent
with studies that have looked at diﬀerent cell types. Edelberg
et al. used bone-marrow-derived endothelial progenitor cells
to treat the aging-associated decline in cardiac angiogenesis.
They showed that transplantation of endothelial progenitor
cells from young mice maintained and restored the angio-
genic function of exogenous cardiac tissue but aged donor
endothelial progenitor cells failed to do so [19]. The ability
of hematopoietic stem cells to reconstitute the immune cells
of irradiated mice in allogenic stem cell transplantations
has also been evaluated. It has been shown that transplants
from young donors signiﬁcantly aﬀected lymphocyte recon-
stitution when compared to aged donors [20]. Similarly, the
eﬃcacy of treating atherosclerosis with hematopoietic and
stromal-enriched cells derived from young and aged marrow
hasbeentestedinamurinemodel.Ithasbeenshownthatthe
atherosclerotic burden was signiﬁcantly greater in mice that
received treatment from old donor cells compared with that
of the young donor cells [21]. On the other hand, this age-
relateddeclineintissuerepairabilitymaybecellspeciﬁcsuch
thatcertaincelltypesarelesspronetotheeﬀectsofagingand
retain their therapeutic potential better than other cell types.
Zhang et al. reported in an ischemic cardiomyopathic heart
model that aged donor smooth muscle cells from 2-year-
old rats were associated with signiﬁcantly improved cardiac
function compared with aged donor MSCs from the same
donor age which had very little beneﬁt [22].
There are diﬀerent possible explanations as to why MSCs
isolated from young donors resulted in greater functional
improvement compared to old donor MSCs. These may be
related to the mechanisms by which MSCs improve cardiac
function after cell therapy including transdiﬀerentiation into
cardiomyocytes and/or paracrine eﬀects through secretion
of various cytokines [23]. The current study demonstrates
that with increasing donor age, the diﬀerentiation potential
of MSCs declines signiﬁcantly. MSCs from older donors
may therefore be less capable of regenerating neomyocytes
resulting in functional deterioration and increased scar over
time. In addition, MSCs from old donors may exhibit
ad i ﬀerent cytokine proﬁle compared to young MSCs. In6 Journal of Tissue Engineering
vitro and animal studies have shown that MSCs implanted in
infracted myocardium resulted in increased gene expression
of interleukin-10 [6], a cytokine that has been demonstrated
to reduce infarct size in animals subjected to myocar-
dial ischemia/reperfusion [24]. Furthermore, our lab has
previously demonstrated that MSCs aﬀected the expres-
sion of tissue inhibitor of metalloproteinase-1 and matrix
metalloproteinase-2, both of which inﬂuence ventricular
remodeling following MI [25]. A reduction of the paracrine
eﬀectofagingMSCsmayconceivablyhaveresultedingreater
scar formation and decreased LV function as observed in the
current study. Nevertheless, other mediators or yet unknown
mechanisms may be responsible for the diﬀerences observed
between young and aged MSCs.
While increasing evidence suggests an age-dependent
decrease in the therapeutic potential of multipotent MSCs,
it would be important to determine what donor age would
providethebesttherapeuticeﬀect.Markeletal.havedemon-
strated an age threshold in which MSCs were able to pro-
vide superior myocardial protection [26]. They compared
neonatal MSCs, approximately 2.5-weeks-old, with adult
MSCs, approximately 9-weeks-old, in a rodent model of
ischemia/reperfusion and showed that adult MSCs were able
to improve cardiac function following ischemia/reperfusion
whileneonatalMSCsprovidednoprotectiveeﬀect,similarto
the control group.
Although we did not compare the eﬀect of recipient age
on MSCs in an acute MI, it has recently been shown that the
age of the recipient is also a critical factor in determining the
host’s response to cell therapy [27, 28]. In a study by Kan
et al. that used an MI model of young and aged rats that
received skeletal myoblasts isolated from young donor rats,
they found that although cardiac function improved in all
the myoblasts recipients in comparison to the control group,
the improvement in young rats was signiﬁcantly greater than
that of the old rats when using donors of the same age [28].
Therefore, it is possible that after a certain age, the recipient
willbeneﬁtlessfromcelltherapythanyoungerrecipientsand
therefore optimizing the age of MSC donors will potentially
beneﬁt this compromised situation.
Therearesomelimitationstothecurrentstudythatmerit
further investigations. First, correlating rodent age to human
age is an imprecise estimate that can be based on various
factors such as life expectancy, the age of puberty, weaning,
and musculoskeletal maturity [29]. Depending on which of
these factors are used as reference, our 56-week-old rat may
correlate to a human ranging from 9-years-old to over 100-
years-old. On the other hand, from the rodent’s life span
point of view, they exceeded over two-thirds of their average
life span. In addition, they had signs of aging such as tumour
growth that is rarely seen in the younger rats. Therefore,
although the precise age is still diﬃcult to conﬁrm in our
study,itislikelythatourﬁndingsreﬂectedtheeﬀectsofaging
MSCs on aging recipients.
The current rodent model is not exactly a common clini-
cal scenario because injecting MSCs into the myocardium 10
minutes after coronary ligation may not necessarily simulate
the clinical setting. However, the use of small rodents is
a well-accepted model for MI and is preferable to study the
mechanisms of stem cell therapy. It provides useful evidence
to form a basis for additional mechanistic studies. Further
investigation into the mechanisms of stem cell therapy will
allow for future studies in larger-animal models and provide
information for evidence-based clinical research trials.
In general, the standard procedure for isolating bone
marrow is invasive and can be fatal for the donor. Thus
theirclinicalapplicationsarenormallylimitedbythelogistic,
economic, and timing issues when harvesting autologous
cells from elderly sick patients. From a clinical perspective,
this study implicates that young allogeneic donor’s stem cells
would be preferable to using autologous stem cells iso-
lated from an aged recipient. Young allogeneic MSCs can
be harvested and mass-produced well in advance, tested for
their functional capabilities, and stored as a standardized
cell population for immediate oﬀ-the-shelf use on any
patient without delay after an acute myocardial infarction.
Such logistic advantages are not available with the use of
autologous MSCs that are currently the cell source of choice.
Moreover, because such allogeneic MSCs can be obtained
from young healthy donors, allogeneic MSCs could be of
great value in patients with genetic cardiomyopathies and
in elderly patients with advanced diabetes, heart failure, or
cachexia whose own MSCs could be dysfunctional.
5. Conclusions
The current study demonstrated that MSCs isolated from
young donors resulted in improved cardiac function and
reduced scar deposition and myocardial injury compared
to MSCs from aged donors when used to treat acute MI
in an aging recipient model. These ﬁndings are clinically
relevant since most of the recipients in the clinical setting
may be elderly patients receiving their own autologous
MSCs. Alternatively, it has been reported that MSCs were
immune tolerant and MSC transplant from human donor
to allogenic patients showed no evidence of rejection even
without administration of immunosuppression [2]. The
current study supports the role of universal donor cells, and
with the use of younger MSC donors, we may optimize the
full potential of cellular cardiomyoplasty.
Acknowledgments
This work is supported in part by a research grant from Nat-
ural Sciences and Engineering Research Council, Canada
and Fonds de la Recherche en Sante du Quebec. A. Paul
acknowledges the ﬁnancial support from NSERC Alexander
Graham Bell Canada Graduate Scholarship.
References
[1] W. Dai, S. L. Hale, B. J. Martin et al., “Allogeneic mesenchymal
stem cell transplantation in postinfarcted rat myocardium:
short- and long-term eﬀects,” Circulation, vol. 112, no. 2, pp.
214–223, 2005.
[ 2 ]J .M .H a r e ,J .H .T r a v e r s e ,T .D .H e n r ye ta l . ,“ Ar a n -
domized, double-blind, placebo-controlled, dose-escalation
study of intravenous adult human mesenchymal stem cellsJournal of Tissue Engineering 7
(prochymal) after acute myocardial infarction,” Journal of the
American College of Cardiology, vol. 54, no. 24, pp. 2277–2286,
2009.
[3] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage
potential of adult human mesenchymal stem cells,” Science,
vol. 284, no. 5411, pp. 143–147, 1999.
[4] F. T¨ ogel, Z. Hu, K. Weiss, J. Isaac, C. Lange, and C. Westen-
felder, “Administered mesenchymal stem cells protect against
ischemic acute renal failure through diﬀerentiation-inde-
pendent mechanisms,” American Journal of Physiology , vol.
289, no. 1, pp. F31–F42, 2005.
[5] P. Niemeyer, J. Vohrer, H. Schmal et al., “Survival of human
mesenchymal stromal cells from bone marrow and adipose
tissue after xenogenic transplantation in immunocompetent
mice,” Cytotherapy, vol. 10, no. 8, pp. 784–795, 2008.
[6] G. Chen, M. Nayan, M. Duong et al., “Marrow stromal cells
for cell-based therapy: the role of antiinﬂammatory cytokines
in cellular cardiomyoplasty,” Annals of Thoracic Surgery, vol.
90, no. 1, pp. 190–197, 2010.
[7] R. Atoui, J. F. Asenjo, M. Duong, G. Chen, R. C. Chiu, and
D. Shum-Tim, “Marrow stromal cells as universal donor cells
for myocardial regenerative therapy: their unique immune
tolerance,” Annals of Thoracic Surgery, vol. 85, no. 2, pp. 571–
579, 2008.
[8] D. Egrise, D. Martin, A. Vienne, P. Neve, and A. Schoutens,
“The number of ﬁbroblastic colonies formed from bone mar-
row is decreased and the in vitro proliferation rate of trabecu-
lar bone cells increased in aged rats,” Bone,v o l .1 3 ,n o .5 ,p p .
355–361, 1992.
[9] R. Quarto, D. Thomas, and C. T. Liang, “Bone progenitor cell
deﬁcitsandtheage-associateddeclineinbonerepaircapacity,”
CalciﬁedTissueInternational,vol.56,no.2,pp.123–129,1995.
[10] A. Stolzing and A. Scutt, “Age-related impairment of mes-
enchymal progenitor cell function,” Aging Cell,v o l .5 ,n o .3 ,
pp. 213–224, 2006.
[11] S. V. Tokalov, S. Gr¨ uner, S. Schindler, A. S. Iagunov, M. Bau-
mann, and N. D. Abolmaali, “A number of bone marrow mes-
enchymal stem cells but neither phenotype nor diﬀerentiation
capacities changes with age of rats,” Molecules and Cells, vol.
24, no. 2, pp. 255–260, 2007.
[12] H. Zheng, J. A. Martin, Y. Duwayri, G. Falcon, and J. A. Buck-
walter, “Impact of aging on rat bone marrow-derived stem cell
chondrogenesis,” Journals of Gerontology,v o l .6 2 ,n o .2 ,p p .
136–148, 2007.
[13] C. Nakanishi, M. Yamagishi, K. Yamahara et al., “Activation
of cardiac progenitor cells through paracrine eﬀects of mes-
enchymal stem cells,” Biochemical and Biophysical Research
Communications, vol. 374, no. 1, pp. 11–16, 2008.
[14] J. Rehman, D. Traktuev, J. Li et al., “Secretion of angiogenic
and antiapoptotic factors by human adipose stromal cells,”
Circulation, vol. 109, no. 10, pp. 1292–1298, 2004.
[15] A. Paul, Y. Ge, S. Prakash, and D. Shum-Tim, “Microencapsu-
lated stem cells for tissue repairing: implications in cell-based
myocardial therapy,” Regenerative Medicine,v o l .4 ,n o .5 ,p p .
733–745, 2009.
[ 1 6 ]A .P a u l ,D .S h u m - T i m ,a n dS .P r a k a s h ,“ I n v e s t i g a t i o no n
PEG integrated alginate-chitosan microcapsules for myocar-
dial therapy using marrow stem cells genetically modiﬁed
by recombinant baculovirus,” Cardiovascular Engineering and
Technology, vol. 1, pp. 154–164, 2010.
[17] S. Davani, A. Marandin, N. Mersin et al., “Mesenchymal
progenitor cells diﬀerentiate into an endothelial phenotype,
enhance vascular density, and improve heart function in a rat
cellular cardiomyoplasty model,” Circulation, vol. 108, pp. II-
253–II-258, 2003.
[18] A.Stolzing,E.Jones,D.McGonagle,andA.Scutt,“Age-related
changes in human bone marrow-derived mesenchymal stem
cells: consequences for cell therapies,” Mechanisms of Ageing
and Development, vol. 129, no. 3, pp. 163–173, 2008.
[19] J. M. Edelberg, L. Tang, K. Hattori, D. Lyden, and S. Raﬁi,
“Youngadultbonemarrow-derivedendothelialprecursorcells
restore aging-impaired cardiac angiogenic function,” Circula-
tion Research, vol. 90, no. 10, pp. E89–E93, 2002.
[ 2 0 ]M .H i r a y a m a ,E .A z u m a ,Q .J i a n ge ta l . ,“ T h er e c o n s t i t u t i o n
of CD45RBhiCD4+ naive T cells is inversely correlated with
donor age in murine allogeneic haematopoietic stem cell
transplantation,” British Journal of Haematology, vol. 111, no.
2, pp. 700–707, 2000.
[21] F. M. Rauscher, P. J. Goldschmidt-Clermont, B. H. Davis
et al., “Aging, progenitor cell exhaustion, and atherosclerosis,”
Circulation, vol. 108, no. 4, pp. 457–463, 2003.
[22] H. Zhang, S. Fazel, H. Tian et al., “Increasing donor age
adversely impacts beneﬁcial eﬀects of bone marrow but not
smooth muscle myocardial cell therapy,” American Journal of
Physiology , vol. 289, no. 5, pp. H2089–H2096, 2005.
[23] M. Gnecchi, H. He, N. Noiseux et al., “Evidence supporting
paracrine hypothesis for Akt-modiﬁed mesenchymal stem
cell-mediated cardiac protection and functional improve-
ment,” Federation of American Societies for Experimental
Biology Journal, vol. 20, no. 6, pp. 661–669, 2006.
[24] T. Kilic, D. Ural, E. Ural et al., “Relation between proinﬂam-
matory to anti-inﬂammatory cytokine ratios and long-term
prognosis in patients with non-ST elevation acute coronary
syndrome,” Heart, vol. 92, no. 8, pp. 1041–1046, 2006.
[25] E. J. Molina, J. Palma, D. Gupta et al., “Reverse remodeling is
associated with changes in extracellular matrix proteases and
tissueinhibitorsaftermesenchymalstemcell(MSC)treatment
of pressure overload hypertrophy,” Journal of Tissue Engineer-
ing and Regenerative Medicine, vol. 3, no. 2, pp. 85–91, 2009.
[26] T. A. Markel, P. R. Crisostomo, M. C. Manukyan et al., “Are
neonatal stem cells as eﬀective as adult stem cells in providing
ischemicprotection?”JournalofSurgicalResearch,vol.152,no.
2, pp. 325–330, 2009.
[27] R.M.Takeuchi,L.Takeuchi,M.Hurtadoetal.,“Ageassociated
responsiveness to allogeneic mesenchymal stem cell (MSC)
transplantation after ischemia-reperfusion (IR) in rats,” Cir-
culation, vol. 120, p. S876, 2009.
[28] C. D. Kan, S. H. Li, R. D. Weisel, S. Zhang, and R. K. Li,
“Recipient age determines the cardiac functional improve-
ment achieved by skeletal myoblast transplantation,” Journal
of the American College of Cardiology, vol. 50, no. 11, pp. 1086–
1092, 2007.
[29] R. Quinn, “Comparing rat’s to human’s age: how old is my rat
in people years?” Nutrition, vol. 21, no. 6, pp. 775–777, 2005.